Jagsonpal Pharmaceuticals Reports Q2 FY27 Results and Strategic Hospital Segment Entry
Jagsonpal Pharmaceuticals Ltd · Outcome · 28 Oct 2026, 11:39 pm
Jagsonpal Pharmaceuticals Reports Q2 FY27 Results and Strategic Hospital Segment Entry Jagsonpal Pharmaceuticals reported standalone revenue from operations of ₹813.75m for the quarter ended 30th Sep'26, up 9.28% YoY, with net profit at ₹125.90m versus ₹125.74m in the previous year quarter. Consolidated revenue stood at ₹963.71m with net profit at ₹122.87m. The company completed an 85% equity acquisition in Aequitas Healthcare for ₹208m effective 1st Jul'26 to enter the hospital segment, incurring ₹2.35m in exceptional deal costs. It also signed a slump sale agreement on 23rd Sep'26 to acquire Group Pharmaceuticals' Wellness Portfolio.
Original exchange filing (PDF)
More announcements from Jagsonpal Pharmaceuticals Ltd
- Earning call transcript for Jagsonpal Pharmaceuticals Limited Q2 FY 27 Earning Conference Call on October 29, 2026 at 2:00 P.M · 03 Nov 2026
- Audio Recording of Jagsonpal Pharmaceuticals Limited Q2 FY27 Earnings Conference call on October 29, 2026 at 02:00 P.M. · 29 Oct 2026
- Press Release for Unaudited Financial Results for the quarter September 30, 2026 · 29 Oct 2026
- Press Release for Unaudited Financial Results for the quarter ended September 30, 2026. · 29 Oct 2026
- Unaudited Financial Results (Standalone & Consolidated for the quarter and half year ended September 30, 2026. · 28 Oct 2026
- Jagsonpal Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 28 Oct 2026
- JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 28 Oct 2026
- Intimation of Analysts/Investors Conference Call · 29 Oct 2026
